- Report
- May 2024
- 128 Pages
Global
From €5786EUR$6,499USD£5,033GBP
- Report
- June 2023
- 112 Pages
Global
From €4006EUR$4,500USD£3,485GBP
- Report
- February 2024
- 120 Pages
Global
From €4229EUR$4,750USD£3,679GBP
- Report
- June 2022
- 120 Pages
Global
From €4229EUR$4,750USD£3,679GBP
- Report
- March 2024
- 221 Pages
Global
From €3205EUR$3,600USD£2,788GBP
- Report
- October 2021
- 288 Pages
Global
From €3205EUR$3,600USD£2,788GBP
- Report
- October 2019
- 128 Pages
Global
From €13349EUR$14,995USD£11,613GBP
- Report
- January 2024
- 138 Pages
United States
€3383EUR$3,800USD£2,943GBP
- Report
- January 2024
- 243 Pages
Global
€4447EUR$4,995USD£3,868GBP
- Report
- October 2023
- 85 Pages
United States
From €4318EUR$4,850USD£3,756GBP
- Report
- October 2022
- 182 Pages
Global
From €1780EUR$2,000USD£1,549GBP
Cosentyx is a biologic drug used to treat immune disorders such as psoriasis, ankylosing spondylitis, and psoriatic arthritis. It is a monoclonal antibody that works by blocking the action of a protein called interleukin-17A (IL-17A). This protein is involved in the inflammation process, which is a key factor in the development of these disorders. Cosentyx is administered as an injection under the skin or as an intravenous infusion.
Cosentyx is a relatively new drug, having been approved by the US Food and Drug Administration in 2015. It is the first and only IL-17A inhibitor approved for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It is also the first biologic drug approved for the treatment of ankylosing spondylitis.
Cosentyx is marketed by Novartis, a Swiss multinational pharmaceutical company. Other companies in the market include AbbVie, Amgen, and Janssen Biotech. Show Less Read more
